Vienna, Austria

Katalin Varadi

USPTO Granted Patents = 20 

 

 

Average Co-Inventor Count = 5.2

ph-index = 5

Forward Citations = 58(Granted Patents)


Company Filing History:


Years Active: 1997-2021

where 'Filed Patents' based on already Granted Patents

20 patents (USPTO):

Title: Katalin Varadi: Innovator in Hemostasis Research

Introduction: Katalin Varadi, based in Vienna, Austria, has made significant contributions to the field of hematology and hemostasis through his groundbreaking inventions. With an impressive portfolio of 20 patents, Varadi's work focuses on improving treatment methodologies for von Willebrand disease (VWD), showcasing his dedication to advancing medical science and patient care.

Latest Patents: Varadi's latest patents include innovative methods for testing the effectiveness of von Willebrand factor (VWF) in treating VWD. These methods involve measuring VWF cleavage fragments in blood samples from patients before and after treatment. An increase in these fragments indicates that endogenous a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) is effectively cleaving the VWF, while a decrease suggests that ADAMTS13 activity is impaired.

Another notable patent focuses on methods for measuring ADAMTS13 activity, specifically concerning VWF fragment cleavage. This invention utilizes various animal models that exhibit ADAMTS13 activity resembling that of humans, allowing for the measurement of cleavage products of recombinant VWF in mammals, particularly in human plasma.

Career Highlights: Throughout his career, Katalin Varadi has worked with prominent companies in the biopharmaceutical industry, including Baxalta GmbH and Baxter International Inc. His experience in these organizations has played a crucial role in the development of therapies aimed at improving outcomes for patients with bleeding disorders.

Collaborations: Varadi has collaborated with esteemed colleagues such as Peter Turecek and Hans-Peter Schwarz, fostering a collective effort to enhance therapeutic approaches in the realm of hemostasis. These partnerships have amplified the potential impact of his innovations within the medical community.

Conclusion: Katalin Varadi's contributions to the realm of hemophilia research through his patented methods and collaborations underscore his role as a leading inventor in this field. With a focus on advancing therapies for von Willebrand disease, Varadi exemplifies the impact of innovation on improving patient care and treatment outcomes in hematology. As he continues to push the boundaries of research, the medical field eagerly anticipates his future discoveries and contributions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…